{"id":119437,"date":"2022-10-14T06:00:58","date_gmt":"2022-10-14T04:00:58","guid":{"rendered":"https:\/\/semmelweis.hu\/hirek\/?p=119437"},"modified":"2022-10-17T08:05:20","modified_gmt":"2022-10-17T06:05:20","slug":"tudomanyos-hirado-12","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/hirek\/2022\/10\/14\/tudomanyos-hirado-12\/","title":{"rendered":"Tudom\u00e1nyos h\u00edrad\u00f3 12."},"content":{"rendered":"
Tudom\u00e1nyos H\u00edrad\u00f3 c\u00edm\u0171 cikksorozatunkban az egyetemhez k\u00f6thet\u0151 D1 min\u0151s\u00edt\u00e9s\u0171 tudom\u00e1nyos k\u00f6zlem\u00e9nyekr\u0151l olvashat\u00f3 r\u00f6vid \u00f6sszefoglal\u00f3. A cikkeket az elm\u00falt id\u0151szak megjelen\u00e9sei alapj\u00e1n a K\u00f6zponti K\u00f6nyvt\u00e1r, illetve dr. Szigeti Gyula innov\u00e1ci\u00f3s igazgat\u00f3 v\u00e1logatta.<\/div>\n
Be\u00fcltethet\u0151 poliaszpartamid alap\u00fa m\u00e1gnesesen vez\u00e9relt sz\u00e1las strukt\u00far\u00e1k m\u00e1gneses hipertermi\u00e1s kezel\u00e9s alkalmaz\u00e1s\u00e1ra<\/h5>\n

\"\"Tudom\u00e1nyos publik\u00e1ci\u00f3nkban olyan aminosav sz\u00e1rmaz\u00e9kon alapul\u00f3 sz\u00e1las rendszereket alak\u00edtottunk ki, melyek szervezetbe \u00fcltethet\u0151k biokompatibilit\u00e1suk \u00e9s hossz\u00fa t\u00e1v\u00fa biodegrad\u00e1bilit\u00e1suknak k\u00f6sz\u00f6nhet\u0151en. A m\u00e1gneses nanor\u00e9szecsk\u00e9ket csapd\u00e1zva tartalmaz\u00f3 rendszer nagyon hasonl\u00edt a szervezetben megtal\u00e1lhat\u00f3 extracellul\u00e1ris m\u00e1trixhoz, mely szinten polimer sz\u00e1lakb\u00f3l \u00e9p\u00fcl fel. A k\u00e9miai kereszk\u00f6t\u00e9seknek k\u00f6sz\u00f6nhet\u0151en nagy mennyis\u00e9g\u0171 folyad\u00e9kot k\u00e9pes megtartani, mely lehet\u0151s\u00e9get ny\u00fajt a kismolekul\u00e1k szabad diff\u00fazi\u00f3j\u00e1nak \u00e9s a p\u00f3rusos szerkezete miatt a sejtek infiltr\u00e1ci\u00f3j\u00e1nak. A m\u00e1gneses nanor\u00e9szecsk\u00e9knek k\u00f6sz\u00f6nhet\u0151en v\u00e1ltakoz\u00f3 m\u00e1gneses t\u00e9rbe helyezve a sz\u00f6veti strukt\u00fara k\u00e9pes ir\u00e1ny\u00edtottan felmeleg\u00edteni k\u00f6rnyezet\u00e9t, ezzel elpuszt\u00edtva a sejteket, mely egy daganatos ter\u00fclet eset\u00e9n kieg\u00e9sz\u00edt\u0151 kezel\u00e9sk\u00e9nt alkalmazhat\u00f3 kemoter\u00e1pi\u00e1s szerek mellett. A r\u00e9szecsk\u00e9k m\u00e1gneses tulajdons\u00e1ga emellett lehet\u0151v\u00e9 teszi, hogy MRI vizsg\u00e1latokkal nyomon k\u00f6vess\u00fck a be\u00fcltet\u00e9st k\u00f6vet\u0151en a laborat\u00f3riumi \u00e1llatokban \u00edgy monitorozva in vivo a szerkezet degrad\u00e1ci\u00f3j\u00e1t \u00e9s a nanor\u00e9szecsk\u00e9k koncentr\u00e1ci\u00f3j\u00e1t az adott ter\u00fcleten az ism\u00e9telt hipertermi\u00e1s kezel\u00e9sek el\u0151tt – foglalta \u00f6ssze dr. Jedlovszky-Hajd\u00fa Ang\u00e9la.<\/p>\n

\n

An Implantable Magneto-Responsive Poly(aspartamide) Based Electrospun Scaffold for Hyperthermia Treatment
\nTam\u00e1s Veres (Laboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University), Constantinos Voniatis (Laboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University; Department of Surgery, Transplantation and Gastroenterology, Semmelweis University), Krist\u00f3f Moln\u00e1r (Laboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University), D\u00e1niel Nesztor (Department of Food Engineering, University of Szeged), Daniella Feh\u00e9r (Heart and Vascular Centre, Department of Surgical Research and Techniques, Semmelweis University), Andrea Ferencz (Heart and Vascular Centre, Department of Surgical Research and Techniques, Semmelweis University), Iv\u00e1n Gresits (Department of Biophysics and Radiation Biology, Semmelweis University), Gy\u00f6rgy Thur\u00f3czy (NRIRR \u201cFr\u00e9d\u00e9ric Joliot-Curie\u201d National Research Institute for Radiobiology and Radiohygiene), Bence G\u00e1bor M\u00e1rkus (Stavropoulos Center for Complex Quantum Matter, Department of Physics and Astronomy, University of Notre Dame; Institute of Physics, Budapest University of Technology and Economics; Wigner Research Centre for Physics Economics), Ferenc Simon (Institute of Physics, Budapest University of Technology and Economics; Wigner Research Centre for Physics Economics), Norbert Marcell Nemes (Grupo de F\u00edsica de Materiales Complejos (GFMC), Departamento de F\u00edsica de Materiales, Universidad Complutense de Madrid), Mar Garc\u00eda-Hern\u00e1ndez (Grupo de F\u00edsica de Materiales Complejos (GFMC), Departamento de F\u00edsica de Materiales, Universidad Complutense de Madrid), Lilla Reiniger (Department of Pathology and Experimental Cancer Research, Semmelweis University), Ildik\u00f3 Horv\u00e1th (Department of Biophysics and Radiation Biology, Semmelweis University), Domokos M\u00e1th\u00e9 (Department of Biophysics and Radiation Biology, Semmelweis University; Hungarian Center of Excellence for Molecular Medicine (HCEMM), In Vivo Imaging Advanced Core Facility, Semmelweis University Site), Kriszti\u00e1n Szigeti (Department of Biophysics and Radiation Biology, Semmelweis University), Etelka Tomb\u00e1cz (Department of Food Engineering, University of Szeged; So\u00f3s Ern\u0151 Water Technology Research and Development Center, University of Pannonia), Angela Jedlovszky-Hajdu (Laboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University)
\nNanomaterials 2022, 12(9), 1476;
\nhttps:\/\/doi.org\/10.3390\/nano12091476<\/a><\/p>\n<\/div>\n

Placeb\u00f3 v\u00e1lasz a szkizofr\u00e9nia negat\u00edv t\u00fcneteinek klinikai vizsg\u00e1lataiban: az eredm\u00e9nyek kritikai \u00fajra\u00e9rt\u00e9kel\u00e9se<\/h5>\n

\"\"A \u201emindenhat\u00f3 placeb\u00f3\u201d hat\u00e1s\u00e1t az orvostudom\u00e1ny a legk\u00fcl\u00f6nb\u00f6z\u0151bb betegs\u00e9gek szinte minden vonatkoz\u00e1sban vizsg\u00e1lta, \u00e9s kett\u0151s-vak, randomiz\u00e1lt, kontroll\u00e1lt klinikai vizsg\u00e1latokkal meggy\u0151z\u0151en demonstr\u00e1lta. Fontos felt\u00e1ratlan ter\u00fcletek maradtakazonban<\/span>\u00a0<\/span>. Ilyen felt\u00e1ratlan ter\u00fcletet k\u00e9pviselnek a szkizofr\u00e9nia negat\u00edv t\u00fcnetei (pl. az akarat cs\u00f6kken\u00e9se, \u00e9rzelmek elsiv\u00e1rosod\u00e1sa), amelyek a legt\u00f6bb jelenleg el\u00e9rhet\u0151 ter\u00e1pi\u00e1ra rendk\u00edv\u00fcl szer\u00e9ny klinikai javul\u00e1st mutatnak, ez\u00e9rt vel\u00fck kapcsolatban egyre s\u00fcrget\u0151bben mer\u00fcl fel \u00faj gy\u00f3gyszerek sz\u00fcks\u00e9gess\u00e9ge. Az \u00faj gy\u00f3gyszerek fejleszt\u00e9se szempontj\u00e1b\u00f3l rendk\u00edv\u00fcl fontos, hogy a negat\u00edv t\u00fcnetek ter\u00fclet\u00e9n a placeb\u00f3 v\u00e1lasz m\u00e9rt\u00e9k\u00e9t \u00e9s prediktorait megismerj\u00fck, hiszen ezzel a kandid\u00e1ns szerek tesztel\u00e9s\u00e9nek hat\u00e9konys\u00e1g\u00e1t jav\u00edthatjuk.<\/span><\/p>\n

Az Egyetem Pszichi\u00e1triai \u00e9s Pszichoter\u00e1pi\u00e1s Klinik\u00e1j\u00e1nak kutat\u00f3csoportja meta-elemz\u00e9sek seg\u00edts\u00e9g\u00e9vel felm\u00e9rte a placeb\u00f3 v\u00e1lasz nagys\u00e1g\u00e1t \u00e9s olyan prediktor t\u00e9nyez\u0151ket azonos\u00edtott, amelyek r\u00e9v\u00e9n klinikai vizsg\u00e1latokban a placeb\u00f3 v\u00e1lasz nagys\u00e1ga jelent\u0151sen cs\u00f6kkenthet\u0151. Az amerikai National Institutes of Mental Health foly\u00f3irat\u00e1ban megjelent cikk tov\u00e1bbi \u00e9rdekess\u00e9ge, hogy felh\u00edvja a figyelmet a szakb\u00edr\u00e1lati rendszer gyenges\u00e9geire is. Nevezetesen, egyetem\u00fcnk kutat\u00f3csoportja az irodalomban egyetlen kor\u00e1bban k\u00f6z\u00f6lt meta-elemz\u00e9s eredm\u00e9nyeit \u00fajra\u00e9rt\u00e9kelve arra a meg\u00e1llap\u00edt\u00e1sra jutott, hogy a szkizofr\u00e9nia szakter\u00fclet\u00e9n legmagasabban jegyzett foly\u00f3iratban megjelent kor\u00e1bbi cikk a placeb\u00f3 v\u00e1lasz hat\u00e1s\u00e1t hib\u00e1s elemz\u00e9sek r\u00e9v\u00e9n kb. \u00f6tsz\u00f6r\u00f6sen t\u00falbecs\u00fclte – fogalmazott \u00f6sszefoglal\u00f3j\u00e1ban dr. Czobor P\u00e1l.<\/span><\/p>\n

\n

Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence
\nP\u00e1l Czobor (Department of Psychiatry and Psychotherapy, Semmelweis University), Brigitta Kakuszi (Department of Psychiatry and Psychotherapy, Semmelweis University), Istv\u00e1n Bitter (Istv\u00e1n Bitter)
\nSchizophrenia Bulletin, sbac061
\nhttps:\/\/doi.org\/10.1093\/schbul\/sbac061<\/a><\/p>\n<\/div>\n

A szinovi\u00e1lis fibroblasztok mint lehets\u00e9ges ter\u00e1pi\u00e1s c\u00e9lpontok rheumatoid arthritisben<\/h5>\n

\"\"A szinovi\u00e1lis fibroblasztok az \u00edz\u00fcleti tok bels\u0151 r\u00e9teg\u00e9nek, az \u00edz\u00fcleti membr\u00e1nnak a n\u00e9lk\u00fcl\u00f6zhetetlen sejtjei, melyek a sejtk\u00f6z\u00f6tti t\u00e9r molekul\u00e1inak termel\u00e9se r\u00e9v\u00e9n, valamint az \u00edz\u00fcleti folyad\u00e9k \u00f6sszet\u00e9tel\u00e9nek m\u00f3dos\u00edt\u00e1s\u00e1val hozz\u00e1j\u00e1rulnak a norm\u00e1l \u00edz\u00fcleti m\u0171k\u00f6d\u00e9shez. Egyes autoimmun folyamatok, p\u00e9ld\u00e1ul a rheumatoid arthritis eset\u00e9ben azonban ezek a sejtek elkezdenek prolifer\u00e1lni \u00e9s fenot\u00edpusos v\u00e1ltoz\u00e1sokon mennek kereszt\u00fcl, mely sor\u00e1n sz\u00f6vetk\u00e1ros\u00edt\u00f3 \u00e9s az immunm\u0171k\u00f6d\u00e9seket befoly\u00e1sol\u00f3 funkci\u00f3juk r\u00e9v\u00e9n k\u00f6zponti elemeiv\u00e9 v\u00e1lnak a gyullad\u00e1s fennmarad\u00e1s\u00e1nak, valamint er\u0151s\u00f6d\u00e9s\u00e9nek. A szinovi\u00e1lis fibroblasztok autoimmun \u00edz\u00fcleti betegs\u00e9gekben bet\u00f6lt\u00f6tt fontos szerepe vonz\u00f3 ter\u00e1pi\u00e1s c\u00e9lpontt\u00e1 teszi \u0151ket.<\/p>\n

Jelen publik\u00e1ci\u00f3nkban \u00e1ttekintett\u00fck, hogy a szinovi\u00e1lis fibroblasztokat mely pontokon lehet g\u00e1tolni rheumatoid arthritisben. Elemezt\u00fck, hogy mik\u00e9nt befoly\u00e1solhat\u00f3 a sejtek differenci\u00e1l\u00f3d\u00e1sa, epigenetik\u00e1ja \u00e9s metabolizmusa, prolifer\u00e1ci\u00f3ja \u00e9s sejthal\u00e1la, jel\u00e1tvitele, m\u00e1s sejtekkel (pl. immunsejtekkel) vagy a sz\u00f6vetk\u00f6zti t\u00e9rrel val\u00f3 kapcsolata, tov\u00e1bb\u00e1 sz\u00f6veti v\u00e1ndorl\u00e1sa. K\u00fcl\u00f6n hangs\u00falyoztuk, hogy mesenchim\u00e1lis-eredet\u00fck r\u00e9v\u00e9n a szinovi\u00e1lis fibroblasztok g\u00e1tl\u00e1sa ak\u00e1r immunszuppressz\u00edv k\u00f6vetkezm\u00e9nyek n\u00e9lk\u00fcl lenne megval\u00f3s\u00edthat\u00f3, mely nem egy elhanyagolhat\u00f3 szempont egy vil\u00e1gj\u00e1rv\u00e1ny sor\u00e1n – \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. N\u00e9meth Tam\u00e1s.<\/p>\n

\n

Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
\nTam\u00e1s N\u00e9meth (Department of Physiology<\/span>,\u00a0Semmelweis University; Department of Rheumatology and Clinical Immunology, Semmelweis University; Department of Internal Medicine and Oncology,\u00a0Semmelweis University), Gy\u00f6rgy Nagy (Department of Rheumatology and Clinical Immunology, Semmelweis University; Department of Internal Medicine and Oncology,\u00a0Semmelweis University; Department of Genetics, Cell and Immunobiology, Semmelweis University; Heart and Vascular Center, Semmelweis University), Thomas Pap (Institute of Musculoskeletal Medicine,\u00a0Medical Faculty of the Westphalian Wilhelm University)
\nAnnals of the Rheumatic Diseases 2022;81:1055-1064.
\nhttp:\/\/dx.doi.org\/10.1136\/annrheumdis-2021-222021<\/a><\/span><\/p>\n<\/div>\n

HunCRC, eszk\u00f6z a vastagb\u00e9lsz\u0171r\u00e9s diagnosztikai MI kifejleszt\u00e9s\u00e9hez<\/h5>\n

\"\"A vastagb\u00e9lr\u00e1k (CRC) napjainkban az egyik leggyakoribb r\u00e1kt\u00edpus, hal\u00e1loz\u00e1sban negyedik, az \u00faj megbeteged\u00e9sek sz\u00e1m\u00e1t tekintve pedig harmadik helyen \u00e1ll vil\u00e1gszerte. Az el\u0151rehaladott betegs\u00e9g rossz kil\u00e1t\u00e1sokkal j\u00e1r, \u00edgy a korai felismer\u00e9s d\u00f6nt\u0151 fontoss\u00e1g\u00fa a t\u00fal\u00e9l\u00e9s szempontj\u00e1b\u00f3l.
\nA vastagb\u00e9lt\u00fckr\u00f6z\u00e9s sor\u00e1n a gyan\u00fas elv\u00e1ltoz\u00e1sokb\u00f3l nyert mint\u00e1t patol\u00f3gusok dolgozz\u00e1k fel, majd sz\u00f6vettani \u00e9rt\u00e9kel\u00e9st v\u00e9geznek (diagn\u00f3zis). A patol\u00f3giai vizsg\u00e1lat c\u00e9lja, hogy v\u00e1laszt adjon a kritikus k\u00e9rd\u00e9sekre, p\u00e9ld\u00e1ul arra, hogy az elv\u00e1ltoz\u00e1s j\u00f3- vagy rosszindulat\u00fa-e. Ezek a param\u00e9terek prognosztikus \u00e9s ter\u00e1pi\u00e1s jelent\u0151s\u00e9ggel b\u00edrnak \u00e9s elengedhetetlenek a sikeres kezel\u00e9shez. Egy m\u00e9ly tanul\u00e1son alapul\u00f3 algoritmus el\u0151re megj\u00f3solhatn\u00e1 a digitaliz\u00e1lt sz\u00f6vettani metszeten a patol\u00f3gus sz\u00e1m\u00e1ra a kiemelt jelent\u0151s\u00e9g\u0171 elv\u00e1ltoz\u00e1sokat. A nagy \u00e1tereszt\u0151k\u00e9pess\u00e9g\u0171 k\u00e9pelemz\u0151 szoftverek seg\u00edthetnek felgyors\u00edtani a patol\u00f3giai diagnosztika folyamat\u00e1t. Ez a d\u00f6nt\u00e9st\u00e1mogat\u00f3 el\u0151sz\u0171r\u00e9s k\u00f6nny\u00edten\u00e9 meg a patol\u00f3gus munk\u00e1j\u00e1t a j\u00f6v\u0151ben.<\/p>\n

Tanulm\u00e1nyunkban 200 digitaliz\u00e1lt k\u00e9pet tett\u00fcnk k\u00f6zz\u00e9, amelyek hematoxilin-eozin fest\u00e9s\u0171, vastagb\u00e9lb\u0151l sz\u00e1rmaz\u00f3, sz\u00f6vettani mint\u00e1kr\u00f3l k\u00e9sz\u00fcltek. V\u00e1rhat\u00f3an a HunCRC \u2012ez a publik\u00e1ci\u00f3nkban r\u00e9szletesen ismertetett adatk\u00e9szlet \u2012, mely sz\u00e9les k\u00f6rben hozz\u00e1f\u00e9rhet\u0151, seg\u00edti majd a j\u00f6v\u0151ben a vastagb\u00e9lr\u00e1k sz\u00e1m\u00edt\u00f3g\u00e9pes diagnosztik\u00e1j\u00e1t, valamint lehet\u0151s\u00e9get teremt a kutat\u00f3k sz\u00e1m\u00e1ra \u00faj, d\u00f6nt\u00e9st\u00e1mogat\u00f3 algoritmusok fejleszt\u00e9s\u00e9re – fogalmazott Kontsek Endre.<\/p>\n

\n

HunCRC: annotated pathological slides to enhance deep learning applications in colorectal cancer screening
\nB\u00e1lint \u00c1rmin Pataki (Department of Physics of Complex Systems, ELTE, E\u00f6tv\u00f6s Lor\u00e1nd University), Alex Olar (Department of Physics of Complex Systems, ELTE, E\u00f6tv\u00f6s Lor\u00e1nd University), Dezs\u0151 Ribli (Department of Physics of Complex Systems, ELTE, E\u00f6tv\u00f6s Lor\u00e1nd University), Adri\u00e1n Pesti (2nd Department of Pathology, Semmelweis University), Endre Kontsek (2nd Department of Pathology, Semmelweis University), Benedek Gy\u00f6ngy\u00f6si (2nd Department of Pathology, Semmelweis University), \u00c1gnes Bilecz (2nd Department of Pathology, Semmelweis University), Tekla Kov\u00e1cs (2nd Department of Pathology, Semmelweis University), Krist\u00f3f Attila Kov\u00e1cs (2nd Department of Pathology, Semmelweis University), Zs\u00f3fia Kramer (2nd Department of Pathology, Semmelweis University), Andr\u00e1s Kiss (2nd Department of Pathology, Semmelweis University), Mikl\u00f3s Sz\u00f3cska (Health Services Management Training Centre, Semmelweis University), P\u00e9ter Pollner (Health Services Management Training Centre, Semmelweis University; MTA-ELTE Statistical and Biological Physics Research Group at Dept. of Biological Physics, E\u00f6tv\u00f6s Lor\u00e1nd University), Istv\u00e1n Csabai (Department of Physics of Complex Systems, ELTE, E\u00f6tv\u00f6s Lor\u00e1nd University)
\nScientific Data volume 9, Article number: 370 (2022)
\nhttps:\/\/doi.org\/10.1038\/s41597-022-01450-y<\/a><\/p>\n<\/div>\n

A koronav\u00edrus fert\u0151z\u00e9s elleni olt\u00e1sok eredm\u00e9nyess\u00e9ge Magyarorsz\u00e1gon<\/h5>\n

\"\"A Semmelweis Egyetem kutat\u00f3i az Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma \u00e1ltal l\u00e9trehozott Epidemiol\u00f3giai \u00e9s Klinikai Kutat\u00e1si munkacsoport tagjaik\u00e9nt a Nemzeti N\u00e9peg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont \u00e9s a Nemzeti Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si Alapkezel\u0151 adataira alapozva elemezt\u00e9k a Magyarorsz\u00e1gon alkalmazott v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9t a mindennapi gyakorlatban. A kutat\u00f3k 3,740,066 oltott f\u0151 eset\u00e9ben vizsg\u00e1lt\u00e1k 5 vakcina (Pfizer-BioNTech, Moderna, Sinopharm Sputnik-V \u00e9s AstraZeneca) eredm\u00e9nyess\u00e9g\u00e9t a SARS-CoV-2 fert\u0151z\u00e9s megel\u0151z\u00e9s\u00e9re \u00e9s a koronav\u00edrushoz k\u00f6thet\u0151 hal\u00e1loz\u00e1sra vonatkoz\u00f3an 2021. janu\u00e1r 22. \u00e9s j\u00fanius 10-e k\u00f6z\u00f6tt. A vizsg\u00e1latban olyan m\u00f3dszertant alkalmaztak, amely nemre, korra \u00e9s j\u00e1rv\u00e1ny intenzit\u00e1s\u00e1ra korrig\u00e1lt eredm\u00e9nyek \u00e9rt\u00e9kel\u00e9s\u00e9t is lehet\u0151v\u00e9 tette. Mind az 5 vizsg\u00e1lt vakcina kiemelked\u0151, 88-98%-os eredm\u00e9nyess\u00e9get mutatott a koronav\u00edrus Alfa vari\u00e1ns\u00e1val \u00f6sszef\u00fcgg\u00e9sbe hozhat\u00f3 hal\u00e1loz\u00e1ssal szemben \u00e9s magas, vagy igen magas v\u00e9delmet (69-89%-os) ny\u00fajtott a megfert\u0151z\u0151d\u00e9ssel szemben.<\/p>\n

A m\u00e1sodik kutat\u00e1s, amely a sorozat harmadik tagjak\u00e9nt ker\u00fclt k\u00f6zl\u00e9sre (HUN-VE 3) 2021. szeptember 13 \u00e9s december 31-e k\u00f6z\u00f6tt (Delta hull\u00e1m) a teljes magyar popul\u00e1ci\u00f3ban m\u00e9rte fel az alapimmuniz\u00e1ci\u00f3t biztos\u00edt\u00f3 Pfizer-BioNTech, Moderna, Sinopharm, Astra Zeneca, Szputnyik \u00e9s Janssen olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9t a koronav\u00edrus-fert\u0151z\u00e9sre, a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 \u00e9s a hal\u00e1loz\u00e1ssal j\u00e1r\u00f3 s\u00falyosabb COVID-19 fert\u0151z\u00e9sre vonatkoz\u00f3an, valamint az alapimmuniz\u00e1ci\u00f3t biztos\u00edt\u00f3 olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9nek id\u0151ben val\u00f3 v\u00e1ltoz\u00e1s\u00e1t. Az alapimmuniz\u00e1ci\u00f3 (2 olt\u00e1s, illetve a Janssen eset\u00e9n 1 olt\u00e1s) eredm\u00e9nyess\u00e9ge a Delta vari\u00e1ns okozta fert\u0151z\u00e9ssel szemben m\u00e1r az els\u0151 n\u00e9gy h\u00f3nap sor\u00e1n is kev\u00e9sb\u00e9 hat\u00e9kony volt, mint a tavaszi Alfa vari\u00e1ns eset\u00e9ben. Ez az eredm\u00e9nyess\u00e9g 6 h\u00f3nap ut\u00e1n meredeken cs\u00f6kkent. Ugyanakkor a s\u00falyosabb mell\u00e9khat\u00e1sok eset\u00e9ben, mint a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st vagy a hal\u00e1loz\u00e1st is eredm\u00e9nyez\u0151 COVID-19 fert\u0151z\u00e9s, az eredm\u00e9nyess\u00e9g a Delta hull\u00e1m sor\u00e1n is jelent\u0151s m\u00e9rt\u00e9kben fennmaradt, b\u00e1r ezen a t\u00e9ren is cs\u00f6kken\u00e9st tapasztaltak az id\u0151 f\u00fcggv\u00e9ny\u00e9ben a kutat\u00f3k. A legeredm\u00e9nyesebbnek az mRNS olt\u00e1sok \u00e9s a Szputnyik vakcina bizonyult, ugyanakkor m\u00e9g ezek eset\u00e9ben is jelent\u0151s tov\u00e1bbi el\u0151nyt ny\u00fajtottak az eml\u00e9keztet\u0151 olt\u00e1sok az \u0151szi hull\u00e1mban. A harmadik olt\u00e1sok eset\u00e9n a leggyakrabban, 95% feletti ar\u00e1nyban az mRNS vakcin\u00e1k ker\u00fcltek bead\u00e1sra, melyek igen jelent\u0151sen, k\u00f6zel 100%-os m\u00e9rt\u00e9kben v\u00e9dt\u00e9k meg a lakoss\u00e1got a koronav\u00edrus-fert\u0151z\u00e9st\u0151l \u00e9s a s\u00falyosabb sz\u00f6v\u0151dm\u00e9nyekt\u0151l. Az eml\u00e9keztet\u0151 olt\u00e1sok a kiindul\u00e1si alapolt\u00e1sokt\u00f3l f\u00fcggetlen\u00fcl 95-100%-os v\u00e9delmet ny\u00fajtottak a koronav\u00edrus hal\u00e1loz\u00e1ssal szemben, 92-98%-os v\u00e9delmet a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 koronav\u00edrus-fert\u0151z\u00e9ssel szemben \u00e9s 88-96%-os v\u00e9delmet a megfert\u0151z\u0151d\u00e9ssel szemben az eml\u00e9keztet\u0151 olt\u00e1st k\u00f6vet\u0151 4 h\u00f3nap sor\u00e1n. A m\u00e9g \u00e9rt\u00e9kelhet\u0151 sz\u00e1mban alkalmazott Janssen \u00e9s Sinopharm eml\u00e9keztet\u0151 olt\u00e1sok eredm\u00e9nyess\u00e9ge enn\u00e9l alacsonyabbnak bizonyult. A munkacsoport olyan statisztikai m\u00f3dszertant alkalmazott a HUN-VE 3 vizsg\u00e1lat sor\u00e1n a kr\u00f3nikus betegs\u00e9gek, kor, nem \u00e9s a j\u00e1rv\u00e1ny intenzit\u00e1s\u00e1nak kiegyens\u00falyoz\u00e1s\u00e1val, amellyel az egyes vakcina t\u00edpusok \u00e9s a kombin\u00e1ci\u00f3k eredm\u00e9nyess\u00e9ge \u00f6sszevethet\u0151v\u00e9 v\u00e1lt.<\/p>\n

A harmadik kutat\u00e1s (HUN-VE 2) az Omikron hull\u00e1m sor\u00e1n m\u00e1r a n\u00e9gy olt\u00e1sban r\u00e9szes\u00fcltek eset\u00e9ben is vizsg\u00e1lta az olt\u00e1skombin\u00e1ci\u00f3k eredm\u00e9nyess\u00e9g\u00e9t. A koronav\u00edrus fert\u0151z\u00e9s mellett fell\u00e9p\u0151 hal\u00e1loz\u00e1s kock\u00e1zata a teljes, 15 \u00e9vn\u00e9l id\u0151sebb magyar popul\u00e1ci\u00f3ban 55%-kal alacsonyabb volt az Omikron hull\u00e1m sor\u00e1n, mint a Delta hull\u00e1mban. Az Omikron hull\u00e1m sor\u00e1n az alapimmuniz\u00e1ltak csoportj\u00e1ba tartoz\u00f3k eset\u00e9ben a koronav\u00edrus hal\u00e1loz\u00e1s es\u00e9lye \u00f6sszess\u00e9g\u00e9ben 40%-kal volt alacsonyabb, mint az oltatlanok popul\u00e1ci\u00f3j\u00e1ban, a h\u00e1rom olt\u00e1s egy\u00fcttesen 82%-os rizik\u00f3cs\u00f6kken\u00e9shez vezetett. N\u00e9gy olt\u00e1s eset\u00e9n k\u00f6zel 100%-os v\u00e9delmet tal\u00e1ltak – \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. Vok\u00f3 Zolt\u00e1n.<\/p>\n

\n

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary\u2014the HUN-VE study
\nZolt\u00e1n Vok\u00f3 (Centre for Health Technology Assessment, Semmelweis University; Syreon Research Institute), Zolt\u00e1n Kiss (Second Department of Medicine and Nephrology-Diabetes Centre, University of P\u00e9cs Medical School), Gy\u00f6rgy Surj\u00e1n (Ministry of Human Resources; Institute of Digital Health Sciences, Semmelweis University), Orsolya Surj\u00e1n (Department of Deputy Chief Medical Officer II, National Public Health Centre), Zs\u00f3fia Barcza (Syntesia Medical Communications Ltd.), Bernadett P\u00e1lyi (National Biosafety Laboratory, Division of Microbiological Reference Laboratories, National Public Health Centre), Eszter Formanek-Balku (Department of Public Health Strategy, Health Development and Health Monitoring, National Public Health Centre), Gerg\u0151 Attila Moln\u00e1r (Second Department of Medicine and Nephrology-Diabetes Centre, University of P\u00e9cs Medical School), R\u00f3bert Herczeg (Szent\u00e1gothai Research Centre, University of P\u00e9cs), Attila Gyenesei (Szent\u00e1gothai Research Centre, University of P\u00e9cs), Attila Miseta (Department of Laboratory Medicine, University of P\u00e9cs Medical School), Lajos Koll\u00e1r (Ministry of Human Resources), Istv\u00e1n Wittmann (Second Department of Medicine and Nephrology-Diabetes Centre, University of P\u00e9cs Medical School), Cec\u00edlia M\u00fcller (Department of Chief Medical Officer, National Public Health Centre), Mikl\u00f3s K\u00e1sler (Ministry of Human Resources)
\nClinical Microbiology and Infection, Volume 28, Issue 3, 2022, Pages 398-404,
\nhttps:\/\/doi.org\/10.1016\/j.cmi.2021.11.011.<\/a><\/p>\n

Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
\nZolt\u00e1n Kiss (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School), Istv\u00e1n Wittmann (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School), L\u0151rinc Polivka (Department of Pulmonology, Semmelweis University), Gy\u00f6rgy Surj\u00e1n (Institute of Digital Health Sciences, Semmelweis University), Orsolya Surj\u00e1n (Department of Deputy Chief Medical Officer II., National Public Health Center), Zs\u00f3fia Barcza (Syntesia Medical Communications Ltd.), Gerg\u0151 Attila Moln\u00e1r (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School), D\u00e1vid Nagy (Center for Health Technology Assessment, Semmelweis University; Syreon Research Institute), Veronika M\u00fcller (Department of Pulmonology, Semmelweis University), Krisztina Bogos (Department of Pulmonology, National Kor\u00e1nyi Institute of Pulmonology), P\u00e9ter Nagy (Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology; Department of Anatomy and Histology, Laboratory of Redox Biology, University of Veterinary Medicine; Institute of Oncochemistry, University of Debrecen), Istv\u00e1n Kenessey (Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University), Andr\u00e1s W\u00e9ber (Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology; Cancer Surveillance Branch, International Agency for Research on Cancer), Mih\u00e1ly P\u00e1losi (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School; Department of Deputy Chief Medical Officer II., National Public Health Center), J\u00e1nos Szl\u00e1vik (South-Pest Hospital Centre \u2013 National Institute for Infectology and Haematology), Zsuzsa Schaff (Department of Pathology, Forensic and Insurance Medicine, Semmelweis University), Zolt\u00e1n Szekanecz (Department of Rheumatology, Faculty of Medicine, University of Debrecen), Cec\u00edlia M\u00fcller (Department of Chief Medical Officer, National Public Health Center), Mikl\u00f3s K\u00e1sler (Ministry of Human Resources), Zolt\u00e1n Vok\u00f3 (Center for Health Technology Assessment, Semmelweis University; Syreon Research Institute)
\nFront. Immunol., 23 June 2022 Sec. Vaccines and Molecular Therapeutics
\nhttps:\/\/doi.org\/10.3389\/fimmu.2022.905585<\/a><\/p>\n

Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study)
\nZolt\u00e1n Vok\u00f3 (Center for Health Technology Assessment, Semmelweis University; Syreon Research Institute), Zolt\u00e1n Kiss (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School), Gy\u00f6rgy Surj\u00e1n (Institute of Digital Health Sciences, Semmelweis University), Orsolya Surj\u00e1n (Department of Deputy Chief Medical Officer II., National Public Health Center), Zs\u00f3fia Barcza (Syntesia Medical Communications Ltd.), Istv\u00e1n Wittmann (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School), Gerg\u0151 Attila Moln\u00e1r (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School), D\u00e1vid Nagy (Center for Health Technology Assessment, Semmelweis University; Syreon Research Institute), Veronika M\u00fcller (Department of Pulmonology, Semmelweis University), Krisztina Bogos (Department of Pulmonology, National Kor\u00e1nyi Institute of Pulmonology), P\u00e9ter Nagy (Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology; Department of Anatomy and Histology, Laboratory of Redox Biology, University of Veterinary Medicine; Institute of Oncochemistry, University of Debrecen), Istv\u00e1n Kenessey (Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University), Andr\u00e1s W\u00e9ber (Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology; Cancer Surveillance Branch, International Agency for Research on Cancer), L\u0151rinc Polivka (Department of Pulmonology, Semmelweis University), Mih\u00e1ly P\u00e1losi (National Health Insurance Fund), J\u00e1nos Szl\u00e1vik (Department of Infectology South-Pest Hospital Centre \u2013 National Institute for Infectology and Haematology), Gy\u00f6rgy Rokszin (Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School; RxTarget Ltd.), Cec\u00edlia M\u00fcller (Department of Chief Medical Officer, National Public Health Center), Zolt\u00e1n Szekanecz (Department of Rheumatology, Faculty of Medicine, University of Debrecen), Mikl\u00f3s K\u00e1sler (Ministry of Human Resources)
\nFront. Immunol., 22 July 2022, Sec. Vaccines and Molecular Therapeutics
\nhttps:\/\/doi.org\/10.3389\/fimmu.2022.919408<\/a><\/p>\n<\/div>\n

Az extracellul\u00e1ris vezikul\u00e1k szerepe az immunit\u00e1sban<\/h5>\n

\"\"Az extracellul\u00e1ris vezikul\u00e1k membr\u00e1nnal k\u00f6r\u00fclvett, a sejtek \u00e1ltal a sejten k\u00edv\u00fcli t\u00e9rbe kibocs\u00e1tott g\u00f6mbszer\u0171 k\u00e9pletek. Kutat\u00e1suk az ut\u00f3bbi k\u00e9t \u00e9vtizedben robban\u00e1sszer\u0171 fejl\u0151d\u00e9snek indult t\u00f6bbek k\u00f6z\u00f6tt annak k\u00f6sz\u00f6nhet\u0151en, hogy a j\u00f6v\u0151ben a biomarkerek \u00e9s ter\u00e1pi\u00e1s eszk\u00f6z\u00f6k \u00faj gener\u00e1ci\u00f3j\u00e1t k\u00e9pviselhetik. A tumorbiol\u00f3gia \u00e9s az \u0151ssejtbiol\u00f3gia ter\u00fclet\u00e9n m\u00e1r j\u00f3lismert szerep\u00fck mellett m\u00e1ra egy\u00e9rtelm\u0171v\u00e9 v\u00e1lt, hogy az extracellul\u00e1ris vezikul\u00e1k alapvet\u0151 \u00e9s \u00e1ltal\u00e1nos szerepet j\u00e1tszanak az immunrendszerben is. Szerep\u00fck sokr\u00e9t\u0171 \u00e9s meghat\u00e1roz\u00f3 a velesz\u00fcletett \u00e9s a szerzett immunit\u00e1sban, a gyullad\u00e1sos folyamatokban, az antig\u00e9nprezent\u00e1ci\u00f3ban. Megtal\u00e1ljuk \u0151ket az immunol\u00f3giai szinapszis ter\u00fclet\u00e9n, \u00e9s kit\u00fcntetett szerepet j\u00e1tszanak a T \u00e9s B sejtek fejl\u0151d\u00e9s\u00e9ben. A fenti alap-immunol\u00f3giai folyamatokban j\u00e1tszott szerep\u00fck mellett jelent\u0151s\u00e9g\u00fck igen nagy a fert\u0151z\u00e9sekkel \u00e9s a daganatokkal szembeni immunv\u00e9dekez\u00e9sben, az autoimmun folyamatok kialakul\u00e1s\u00e1ban vagy azok megakad\u00e1lyoz\u00e1s\u00e1ban. Alkalmazhat\u00f3k vakcinak\u00e9nt, \u00e9s az immunter\u00e1pia (pl. a COVID19 ter\u00e1pi\u00e1j\u00e1nak vagy a tumorter\u00e1pia) fontos eszk\u00f6zei lehetnek a j\u00f6v\u0151ben – fogalmazott dr. Buz\u00e1s Edit.\u00a0<\/p>\n

\n

The roles of extracellular vesicles in the immune system
\nEdit I. Buzas (Department of Genetics, Cell and Immunobiology, Semmelweis University; HCEMM-SU Extracellular Vesicles Research Group; ELKH-SE Immune-Proteogenomics Extracellular Vesicles Research Group)
\nNat Rev Immunol (2022)
\nttps:\/\/doi.org\/10.1038\/s41577-022-00763-8<\/a><\/p>\n<\/div>\n

RT 1 oszt\u00e1ly\u00fa \u00ednyvisszah\u00faz\u00f3d\u00e1sok kezel\u00e9se m\u00f3dos\u00edtott koron\u00e1lisan elcs\u00fasztatott tunnel technik\u00e1val, kollag\u00e9n m\u00e1trix-szal vagy sz\u00e1jpadl\u00e1sb\u00f3l sz\u00e1rmaz\u00f3 k\u00f6t\u0151sz\u00f6veti szabadlebennyel: 9 \u00e9ves eredm\u00e9nyek egy prospekt\u00edv randomiz\u00e1lt klinikai vizsg\u00e1latb\u00f3l<\/h5>\n

\"\"Az \u00ednyvisszah\u00faz\u00f3d\u00e1s sor\u00e1n a fog nyaki r\u00e9sze v\u00e1lik l\u00e1that\u00f3v\u00e1. Ez sz\u00e1mos szubjekt\u00edv \u00e9s objekt\u00edv probl\u00e9m\u00e1val p\u00e1rosul. A p\u00e1cienseket legink\u00e1bb zavar\u00f3 eszt\u00e9tikai probl\u00e9ma t\u00e1rsulhat fognyaki \u00e9rz\u00e9kenys\u00e9ggel, fokozott szuvasod\u00e1si hajlammal \u00e9s nehez\u00edtett egy\u00e9ni sz\u00e1jhigi\u00e9n\u00e9vel. A kialakult anat\u00f3miai deformit\u00e1s helyre\u00e1ll\u00edt\u00e1s\u00e1ra m\u00f3dos\u00edtott koron\u00e1lisan elcs\u00fasztatott tunnel technik\u00e1t (MCAT) alkalmaztuk egy 2013-ban publik\u00e1lt vizsg\u00e1latunkban. Ennek a kutat\u00e1snak a hossz\u00fat\u00e1v\u00fa, 9 \u00e9ves ki\u00e9rt\u00e9kel\u00e9s\u00e9t v\u00e9gezt\u00fck el, mely a szakirodalomban hi\u00e1nyp\u00f3tl\u00f3nak sz\u00e1m\u00edt.<\/p>\n

A vizsg\u00e1latban a p\u00e1ciensek k\u00e9toldali t\u00f6bbsz\u00f6r\u00f6s recesszi\u00f3val rendelkeztek, melyeket MCAT technik\u00e1val kezelt\u00fck az egyik oldalt sz\u00e1jpadl\u00e1sb\u00f3l sz\u00e1rmaz\u00f3 k\u00f6t\u0151sz\u00f6veti szabadlebennyel (kontroll), a m\u00e1sik oldalt pedig egy sert\u00e9s eredet\u0171 kollag\u00e9n m\u00e1trix-szal (teszt). Az adatok alapj\u00e1n az \u00e1tlagos gy\u00f6k\u00e9rfelsz\u00edn fed\u00e9s 9 \u00e9v alatt mind a kontroll- mind a tesztcsoportban jelent\u0151s maradt, mindemellett a fels\u0151 \u00e1llcsonton az el\u00e9rt eszt\u00e9tikai eredm\u00e9ny stabilabbnak mutatkozott. A fentiek alapj\u00e1n mindk\u00e9t sz\u00f6vetp\u00f3tl\u00f3 elj\u00e1r\u00e1s hossz\u00fa t\u00e1von sikeresnek bizonyult – fogalmazott dr. Moln\u00e1r B\u00e1lint.<\/p>\n

\n

Treatment of multiple adjacent RT 1 gingival recessions with the modified coronally advanced tunnel (MCAT) technique and a collagen matrix or palatal connective tissue graft: 9-year results of a split-mouth randomized clinical trial
\nB. Moln\u00e1r (Department of Periodontology, Semmelweis University), S. Aroca (Department of Periodontology, School of Dental Medicine, University of Bern), A. Dobos (Department of Periodontology, Semmelweis University), K. Orb\u00e1n (Department of Periodontology, Semmelweis University), J. Szab\u00f3 (Department of Periodontology, Semmelweis University), P. Windisch (Department of Periodontology, Semmelweis University), A. St\u00e4hli (Department of Periodontology, School of Dental Medicine, University of Bern), A. Sculean (Department of Periodontology, School of Dental Medicine, University of Bern)
\nClin Oral Invest (2022).
\nhttps:\/\/doi.org\/10.1007\/s00784-022-04674-9<\/a><\/p>\n<\/div>\n

A r\u00f6vid \u00f6sszefoglal\u00f3kat a tudom\u00e1nyos publik\u00e1ci\u00f3k szerz\u0151i k\u00e9sz\u00edtett\u00e9k.
\nSzerkesztette: Szab\u00f3 \u00c1d\u00e1m
\nFot\u00f3: a publik\u00e1ci\u00f3kb\u00f3l sz\u00e1rmaz\u00f3 k\u00e9pek; Kov\u00e1cs Attila – Semmelweis Egyetem (illusztr\u00e1ci\u00f3)<\/p>\n","protected":false},"excerpt":{"rendered":"

Cikksorozatunkban az egyetemhez k\u00f6thet\u0151 D1 min\u0151s\u00edt\u00e9s\u0171 tudom\u00e1nyos k\u00f6zlem\u00e9nyekr\u0151l olvashat\u00f3 r\u00f6vid \u00f6sszefoglal\u00f3.<\/p>\n","protected":false},"author":101751,"featured_media":102156,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[161,168],"tags":[4276],"class_list":["post-119437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tudomany","category-kiemelt","tag-tudomanyos-hirado"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/119437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/users\/101751"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/comments?post=119437"}],"version-history":[{"count":4,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/119437\/revisions"}],"predecessor-version":[{"id":120878,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/119437\/revisions\/120878"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media\/102156"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media?parent=119437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/categories?post=119437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/tags?post=119437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}